Home » Stocks » MCRB

Seres Therapeutics, Inc. (MCRB)

Stock Price: $25.54 USD 0.41 (1.61%)
Updated December 3, 11:33 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 2.33B
Revenue (ttm) 23.27M
Net Income (ttm) -89.65M
Shares Out 83.53M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $25.54
Previous Close $25.13
Change ($) 0.41
Change (%) 1.61%
Day's Open 25.20
Day's Range 25.17 - 26.10
Day's Volume 202,313
52-Week Range 2.64 - 37.73

More Stats

Market Cap 2.33B
Enterprise Value 2.07B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 83.53M
Float n/a
EPS (basic) -1.17
EPS (diluted) -1.20
FCF / Share -1.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.07M
Short Ratio 8.92
Short % of Float n/a
Beta 4.60
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 100.12
PB Ratio 14.08
Revenue 23.27M
Operating Income -89.42M
Net Income -89.65M
Free Cash Flow -90.33M
Net Cash 256.09M
Net Cash / Share 2.81
Gross Margin -196.09%
Operating Margin -384.24%
Profit Margin -385.20%
FCF Margin -388.11%
ROA -23.27%
ROE -115.06%
ROIC -113.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$37.50*
(46.86% upside)
Low
24.0
Current: $25.54
High
49.0
Target: 37.50
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue34.5128.2732.1021.77----
Revenue Growth22.07%-11.94%47.48%-----
Gross Profit34.5128.2732.1021.77----
Operating Income-71.88-100-91.40-92.84-54.86-15.08-6.05-3.03
Net Income-70.28-98.94-89.38-91.58-54.78-16.71-6.10-3.13
Shares Outstanding56.6540.7440.4539.8523.536.756.395.73
Earnings Per Share-1.24-2.43-2.21-2.30-2.33-2.67-1.09-0.59
Operating Cash Flow-76.52-62.85-75.5243.92-40.84-10.36-5.32-2.93
Capital Expenditures-1.00-1.94-4.68-21.49-4.36-1.00-0.17-0.29
Free Cash Flow-77.52-64.79-80.2022.43-45.21-11.36-5.50-3.22
Cash & Equivalents94.8285.931501952071141.69-
Total Debt44.78----2.500.84-
Net Cash / Debt50.0485.931501952071120.85-
Assets1321201902732171172.13-
Liabilities18116912914011.517.991.66-
Book Value-48.32-48.0560.70133205-26.72-11.12-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Seres Therapeutics, Inc.
Country United States
Employees 108
CEO Eric Shaff

Stock Information

Ticker Symbol MCRB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MCRB
IPO Date June 26, 2015

Description

Seres Therapeutics, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.